Physician profile
Tracy Simonsen
NPI 1023195005
$1,753.47
in general payments reported to CMS, 2019-2025
24 companies · $594 in 2025
The $594 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $103 · 2023: $402 · 2024: $541 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $260.35 | 2023-2025 | |
| Astellas Pharma US INC | $186.74 | 2021-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $162.92 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $160.32 | 2023-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $122.21 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $108.63 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.55 | 2024-2025 | Xifaxan |
| Amgen INC. | $100.31 | 2024-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $97.19 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $48.45 | 2023-2024 | |
| Baxter Healthcare | $46.29 | 2024 | Hillrom - Monarch Airway Clearance System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.40 | 2023-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $42.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.44 | 2023-2025 | Trintellix |
| Abiomed | $30.92 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28.19 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.38 | 2022 | |
| Idorsia Pharmaceuticals US INC | $23.62 | 2023 | Quviviq |
| Shield Therapeutics INC | $22.97 | 2025 | |
| Exact Sciences Corporation | $22.65 | 2023 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $22.37 | 2024 | Ultomiris |
| Lundbeck LLC | $19.16 | 2025 | Rexulti |
| Dexcom, INC. | $19.09 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $19.00 | 2025 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Simonsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.